Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: DATROWAY Type II Variation Application validated in the EU as first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy The […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: JSKN003 was granted Breakthrough Therapy Designation by the FDA for the treatment of PROC Alphamab Oncology announced that the U.S. FDA has granted Breakthrough Therapy Designation to JSKN003 for the treatment of adult patients with […]
Weekly Digest – December 2025 Weekly Digest – December 2025 15 December 2025: Huadong Medicine announced that HDM2012 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for two indications: gastric cancer or gastroesophageal junction cancer and pancreatic cancer Huadong […]
Weekly Digest – December 2025 Weekly Digest – December 2025 16 December 2025: Cellectar Biosciences announces strategic supply agreement with Ionetix for Actinium-225 and Astatine-211 to advance targeted alpha therapies Cellectar Biosciences announced a multi-year strategic supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of the alpha-emitting radioisotopes […]
Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: OBI-902 receives consecutive FDA Orphan Drug Designation indication expanded to gastric cancer including gastroesophageal junction adenocarcinoma OBI Pharma has received a major boost in its oncology pipeline, […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA GSK’s B7-H3–targeted antibody-drug conjugate, Risvutatug rezetecan (GSK’227), has gained fresh […]
Weekly Digest – December 2025 Weekly Digest – December 2025 09 December 2025: DESTINY-Ovarian01 Phase 3 Trial of ENHERTU initiated as first-line maintenance therapy in patients with HER2 expressing advanced ovarian cancer The DESTINY-Ovarian01 Phase 3 trial has reached a […]
Weekly Digest – December 2025 Weekly Digest – December 2025 11 December 2025: Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress Biohaven reported new clinical […]
Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: Korea BNC and ProAbtek jointly develop Albubody’s dual-target next-generation ADC anticancer drug Korea BNC and ProAbTech signed a joint R&D deal to develop dual-target ADCs powered by […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: Oxford BioTherapeutics enters into a strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer Oxford BioTherapeutics (OBT) and GSK have […]
